Home
ALXO
ALXO News

Latest ALX Oncology Holdings Inc. (ALXO) News on February 22, 2025

February 2025 US Penny Stocks With Promising Prospects

Simply Wall St.

3 days ago

February 2025 US Penny Stocks With Promising Prospects

ALX Oncology to Host Virtual R&D Day on March 5, 2025

GlobeNewswire

4 days ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

MT Newswires

a month ago

UBS Cuts Price Target on ALX Oncology Holdings to $2.20 From $4, Keeps Buy Rating

ALX Oncology Shares Drop 15% Following Positive Phase 2

GuruFocus.com

a month ago

ALX Oncology Shares Drop 15% Following Positive Phase 2

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

GlobeNewswire

a month ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

GlobeNewswire

a month ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

MT Newswires

a month ago

Sector Update: Health Care

MT Newswires

a month ago

ALX Oncology Names New CFO; Shares Rise

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

GlobeNewswire

a month ago

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

GlobeNewswire

a month ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

3 US Penny Stocks With Market Caps Under $100M To Watch

Simply Wall St.

a month ago

3 US Penny Stocks With Market Caps Under $100M To Watch

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

Zacks

a month ago

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a month ago

ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

2 months ago

Sector Update: Health Care

MT Newswires

2 months ago

Top Midday Decliners

MT Newswires

2 months ago

ALX Oncology Shares Fall After Downgrade From Jefferies

Investing.com

2 months ago

Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold'

MT Newswires

2 months ago

Jefferies Downgrades ALX Oncology to Hold From Buy, Cuts Price Target to $2 From $12

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

GlobeNewswire

2 months ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

GlobeNewswire

2 months ago

ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

GlobeNewswire

2 months ago

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

3 US Penny Stocks With Market Caps Over $30M To Consider

Simply Wall St.

3 months ago

3 US Penny Stocks With Market Caps Over $30M To Consider

ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

3 months ago

ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

3 months ago

ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

GlobeNewswire

3 months ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

3 months ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Announces November Investor Conference Participation

GlobeNewswire

4 months ago

ALX Oncology Announces November Investor Conference Participation

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

GlobeNewswire

4 months ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc

GuruFocus.com

4 months ago

Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire

5 months ago

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

GlobeNewswire

6 months ago

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

MT Newswires

6 months ago

UBS Adjusts Price Target on ALX Oncology to $4 From $25, Maintains Buy Rating

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

6 months ago

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

GlobeNewswire

7 months ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients

Benzinga

7 months ago

Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients

MT Newswires

7 months ago

Top Premarket Decliners

ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial

Clinical Trials Arena

7 months ago

ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

GlobeNewswire

7 months ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

GlobeNewswire

7 months ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

Zacks

7 months ago

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag

Zacks

7 months ago

Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag

Dianthus (DNTH) Gains 18% in the Past Month: Here's Why

Zacks

7 months ago

Dianthus (DNTH) Gains 18% in the Past Month: Here's Why

Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe

Zacks

8 months ago

Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

Zacks

8 months ago

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates

Zacks

8 months ago

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

Zacks

8 months ago

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

Zacks

8 months ago

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

Zacks

8 months ago

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug

Zacks

8 months ago

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug

Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

Zacks

8 months ago

Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug

Zacks

8 months ago

Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug

Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal

Zacks

8 months ago

Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

Zacks

8 months ago

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion

Zacks

8 months ago

Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion

Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals

Zacks

8 months ago

Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

Zacks

8 months ago

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals

Zacks

8 months ago

JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals

Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

Zacks

8 months ago

Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals

Zacks

8 months ago

Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

Zacks

8 months ago

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 06/18/2024

Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO)

GuruFocus.com

8 months ago

Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO)

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug

Zacks

8 months ago

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

Zacks

8 months ago

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up

Zacks

8 months ago

Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

Zacks

8 months ago

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

Zacks

8 months ago

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

Replimune (REPL) Gains on Positive Data From Melanoma Study

Zacks

8 months ago

Replimune (REPL) Gains on Positive Data From Melanoma Study

Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%

Zacks

8 months ago

Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%

Vir Biotechnology (VIR) Up on Positive Data From HDV Study

Zacks

9 months ago

Vir Biotechnology (VIR) Up on Positive Data From HDV Study

Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals

Zacks

9 months ago

Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals

Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)

Zacks

9 months ago

Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

Zacks

9 months ago

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data

Zacks

9 months ago

Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data

AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

Zacks

9 months ago

AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround

Zacks

9 months ago

Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

GlobeNewswire

9 months ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

Novartis (NVS) Reports Positive Long-Term Data on CSU Drug

Zacks

9 months ago

Novartis (NVS) Reports Positive Long-Term Data on CSU Drug

Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal

Zacks

9 months ago

Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal

Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study

Zacks

9 months ago

Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

Zacks

9 months ago

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

Zacks

9 months ago

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

Zacks

9 months ago

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

Zacks

9 months ago

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

GlobeNewswire

9 months ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

Zacks

9 months ago

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data

Zacks

9 months ago

Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

Zacks

9 months ago

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M

Zacks

9 months ago

Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M

Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why

Zacks

9 months ago

Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why

Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar

Zacks

9 months ago

Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar

Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares

GuruFocus.com

9 months ago

Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares

Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet

Zacks

9 months ago

Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet

GuruFocus.com

9 months ago

ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

9 months ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

MT Newswires

9 months ago

Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing

ALX Oncology Appoints Allison Dillon as Chief Business Officer

GlobeNewswire

9 months ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer

GlobeNewswire

10 months ago

ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

GlobeNewswire

10 months ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

Zacks

10 months ago

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

Share on Social Networks: